Browse study websites

Discover. Prevent. Cure.

Menu Fundraise Donate

    Recommended pages

      Do you mean

        161-170 of 10886 results

        Refine search

        Accentuating the positive to support student behaviour

        One third of Australia’s children will be better supported at school, thanks to a Telethon Kids Institute evidence review of what works best to ...

        Gut bacteria not the cause of autism

        Credit: Chloe Yap from Mater Research and The University of Queensland A long-held belief linking gut bacteria to autism has been debunked by an ...

        Research

        Heritable and environmental determinants of hospitalisation for common childhood illnesses

        David Burgner, Nick de Klerk, Kim Carter   Infection is the leading cause of global child mortality and morbidity, and in Australia the commonest ...

        Research

        GAMA project

        Melinda Judge, Erica Parker, Denise Naniche, Lucia Pastor, Kim W Carter, Denise Anderson, Peter LeSouëf.   This is the largest acute HIV cohort ...

        Could a vaccine help fight food allergies?

        Mailing list MEDIA ENQUIRIES Discover. Prevent. Cure. In the news Be Inspired Media Contacts About Telethon Kids Institute A dramatic rise in food ...

        The Raine Study: three decades of life-changing research

        The Raine Study findings have shown... What is the Raine Study? Ditza said being part of the Raine Study for so long had provided an opportunity for ...

        Research

        Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial

        CDKL5 deficiency disorder (CDD) is a rare developmental and epileptic encephalopathy. Ganaxolone, a neuroactive steroid, reduces the frequency of major motor seizures in children with CDD. This analysis explored the effect of ganaxolone on non-seizure outcomes.  ...

        Research

        Patient-advocate-led global coalition adapting fit-for-purpose outcomes measures to assure meaningful inclusion of DEEs in clinical trials

        Existing clinical tools that measure non-seizure outcomes lack the range and granularity needed to capture skills in developmental and epileptic encephalopathy (DEE)-affected individuals who also fall in the severe to profound range of intellectual disability. This effectively excludes those with severe impairments from clinical trials, impeding the ability of sponsors to evaluate disease-modifying therapies. ...

        Research

        Efficacy thresholds and target populations for antiviral COVID-19 treatments to save lives and costs: a modelling study

        In 2023 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared endemic, yet hospital admissions have persisted and risen within populations at high and moderate risk of developing severe disease, which include those of older age, and those with co-morbidities. Antiviral treatments, currently only available for high-risk individuals, play an important role in preventing severe disease and hospitalisation within this subpopulation. ...

        Research

        The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program

        Transcriptional cofactors of the ETO family are recurrent fusion partners in acute leukemia. We characterized the ETO2 regulome by integrating transcriptomic and chromatin binding analyses in human erythroleukemia xenografts and controlled ETO2 depletion models. We demonstrate that beyond its well-established repressive activity, ETO2 directly activates transcription of MYB, among other genes. ...

        Page 17 of 1089